Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma

PURPOSE: This phase III trial evaluated the efficacy and safety of pazopanib versus placebo in patients with locally advanced renal cell carcinoma (RCC) at high risk for relapse after nephrectomy. PATIENTS AND METHODS: A total of 1,538 patients with resected pT2 (high grade) or ≥ pT3, including N1,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Motzer, Robert J., Haas, Naomi B., Donskov, Frede, Gross-Goupil, Marine, Varlamov, Sergei, Kopyltsov, Evgeny, Lee, Jae Lyun, Melichar, Bohuslav, Rini, Brian I., Choueiri, Toni K., Zemanova, Milada, Wood, Lori A., Reaume, M. Neil, Stenzl, Arnulf, Chowdhury, Simon, Lim, Ho Yeong, McDermott, Ray, Michael, Agnieszka, Bao, Weichao, Carrasco-Alfonso, Marlene J., Aimone, Paola, Voi, Maurizio, Doehn, Christian, Russo, Paul, Sternberg, Cora N.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6018511/
https://ncbi.nlm.nih.gov/pubmed/28902533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.73.5324
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados